Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
GHK-Cu and Rosuvastatin Interaction: Safety, Mechanisms, and Clinical Guidance At a glance Direct interaction evidence / none published as of May 2026 GHK-Cu metabolism / peptidase degradation, not CYP-mediated Rosuvastatin metabolism / minimal CYP2C9, primarily OATP1B1/1B3 hepatic uptake Overlapping CYP liability / none identified Copper load concern / low at typical GHK-Cu doses (1-3 mg/day subcutaneous) Rosuvastatin muscle risk / myopathy incidence approximately 0.1% per FDA label Monitoring recommendation / CK at baseline and if symptoms arise
CD20, CD80, CD3, CD11a, CD19, cluster of differentiation (CD)-20, -80, -3, -11a, -19, respectively
As a spore-former, it is inherently shelf-stable and designed to survive gastric acid transit
Short-chain fatty acids affect immune cell function, leading to changes in the levels of released cytokines and reactive oxygen species
There is a chance that peptides besides GLP-1s will eventually be demonstrated to provide health outcome benefits as seen in rodent pre-clinical models
Why indeed would anyone take such a chance
